Happy Genmab CEO: "We have a pipeline as a mid-sized pharma company"
Danish Genmab expects its pipeline to contain seven clinical projects before the end of the year. CEO Jan van de Winkel is excited and ready to enter new partnerships with some of the programs.
Although the cancer drug Darzalex keeps bringing in millions to Genmab, the Danish biotech firm is working to find the next "star of the show". In the coming months, the company expects to add two new tickets to the pipeline tombola.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
